Hepatic angiosarcoma (HA) is a particularly rare, non-cirrhotic, primary malignancy of the liver, accounting for 2% of liver cancers [1]. However, it is still considered to be the third most common primary hepatic malignancy. HA is a high-grade, aggressive tumor. Surgery is the primary method of treatment for angiosarcoma. Chemotherapy and/or radiation therapy can be an important part of the treatment plan, and they may be administered before or after surgery. The chemotherapy of choice for angiosarcomas has been doxorubicin, and some centers use a combination of mesna, doxorubicin, and ifosfamide (MAI). Liposomal Doxorubicin has also been utilized. Paclitaxel and Docetaxel have shown effectiveness against angiosarcomas of the head, neck and scalp.

Source
Source